{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:52:01Z","timestamp":1792036321064,"version":"4.4.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"DOI":"10.1093\/hmg\/ddt615","type":"journal-article","created":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T02:34:57Z","timestamp":1386124497000},"page":"2251-2265","source":"Crossref","is-referenced-by-count":102,"title":["FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease"],"prefix":"10.1093","volume":"23","author":[{"given":"Alba","family":"Di Pardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Favellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Castrataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fucile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Squitieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Maglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,12,2]]},"reference":[{"key":"key\n\t\t\t\t20170503074603_DDT615C1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/B978-0-12-381328-2.00013-4","article-title":"Huntington's disease: clinical presentation and treatment","volume":"98","author":"Novak","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"key\n\t\t\t\t20170503074603_DDT615C2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"T.H.s.D.C.R. Group","year":"1993","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170503074603_DDT615C3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"key":"key\n\t\t\t\t20170503074603_DDT615C4","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s00018-006-6242-0","article-title":"Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies","volume":"63","author":"Borrell-Pages","year":"2006","journal-title":"Cell. Mol. Life. Sci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C5","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1523\/JNEUROSCI.6348-09.2010","article-title":"Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1","volume":"30","author":"Maglione","year":"2010","journal-title":"J. Neurosci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4155\/fmc.12.25","article-title":"Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis","volume":"4","author":"Chiba","year":"2012","journal-title":"Future Med. Chem."},{"key":"key\n\t\t\t\t20170503074603_DDT615C7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40265-013-0030-6","article-title":"Drugs in development for relapsing multiple sclerosis","volume":"73","author":"Ali","year":"2013","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170503074603_DDT615C8","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1042\/bst0311216","article-title":"Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways","volume":"31","author":"Spiegel","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"key\n\t\t\t\t20170503074603_DDT615C9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","article-title":"Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology","volume":"115","author":"Brinkmann","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"key\n\t\t\t\t20170503074603_DDT615C10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pharmthera.2007.08.005","article-title":"Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis","volume":"117","author":"Dev","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"key\n\t\t\t\t20170503074603_DDT615C11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1124\/dmd.105.009001","article-title":"Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses","volume":"34","author":"Meno-Tetang","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"key\n\t\t\t\t20170503074603_DDT615C12","doi-asserted-by":"crossref","first-page":"47408","DOI":"10.1074\/jbc.M307687200","article-title":"Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases","volume":"278","author":"Billich","year":"2003","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503074603_DDT615C13","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503074603_DDT615C14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2008.06.031","article-title":"Central nervous system-directed effects of FTY720 (fingolimod)","volume":"274","author":"Miron","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.neuropharm.2006.11.010","article-title":"Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors","volume":"52","author":"Osinde","year":"2007","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t20170503074603_DDT615C16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/jpet.107.123927","article-title":"The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors","volume":"323","author":"Coelho","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"key\n\t\t\t\t20170503074603_DDT615C17","first-page":"A373","article-title":"FTY720 induces BDNF production in neuronal cell cultures","volume":"70","author":"Deogracias","year":"2008","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170503074603_DDT615C18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.004","article-title":"Fingolimod protects cultured cortical neurons against excitotoxic death","volume":"67","author":"Di Menna","year":"2012","journal-title":"Pharmacol. Res."},{"key":"key\n\t\t\t\t20170503074603_DDT615C19","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1073\/pnas.1206093109","article-title":"Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome","volume":"109","author":"Deogracias","year":"2012","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170503074603_DDT615C20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.2009060662","article-title":"Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury","volume":"21","author":"Bajwa","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"key\n\t\t\t\t20170503074603_DDT615C21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neulet.2012.04.004","article-title":"FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells","volume":"516","author":"Stessin","year":"2012","journal-title":"Neurosci. Lett."},{"key":"key\n\t\t\t\t20170503074603_DDT615C22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbamcr.2007.11.008","article-title":"Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures","volume":"1783","author":"Brunati","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"key\n\t\t\t\t20170503074603_DDT615C23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170503074603_DDT615C24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/hmg\/ddi443","article-title":"Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1\/2 protects against mutant huntingtin-associated toxicity","volume":"15","author":"Apostol","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170503074603_DDT615C25","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1460-9568.2005.03985.x","article-title":"Akt is altered in an animal model of Huntington's disease and in patients","volume":"21","author":"Colin","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C26","doi-asserted-by":"crossref","first-page":"37445","DOI":"10.1074\/jbc.M110.125542","article-title":"Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway","volume":"285","author":"Varma","year":"2010","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503074603_DDT615C27","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/j.1471-4159.2006.04319.x","article-title":"Myelin-associated glycoprotein (MAG): past, present and beyond","volume":"100","author":"Quarles","year":"2007","journal-title":"J. Neurochem."},{"key":"key\n\t\t\t\t20170503074603_DDT615C28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","article-title":"Protein aggregates in Huntington's disease","volume":"238","author":"Arrasate","year":"2012","journal-title":"Exp. Neurol."},{"key":"key\n\t\t\t\t20170503074603_DDT615C29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jnr.20344","article-title":"Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF","volume":"78","author":"Cepeda","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"key\n\t\t\t\t20170503074603_DDT615C30","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1074\/jbc.M807438200","article-title":"Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner","volume":"284","author":"Lahiri","year":"2009","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503074603_DDT615C31","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1073\/pnas.1114502109","article-title":"Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice","volume":"109","author":"Di Pardo","year":"2012","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170503074603_DDT615C32","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20170503074603_DDT615C33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nchembio.582","article-title":"Kinase inhibitors modulate huntingtin cell localization and toxicity","volume":"7","author":"Atwal","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"key\n\t\t\t\t20170503074603_DDT615C34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007890-199601270-00006","article-title":"A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation","volume":"61","author":"Suzuki","year":"1996","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20170503074603_DDT615C35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbr.2013.06.016","article-title":"Neurorestorative effect of FTY720 in a rat model of Alz'eimer's disease: Comparison with Memantine","volume":"252C","author":"Hemmati","year":"2013","journal-title":"Behav. Brain Res."},{"key":"key\n\t\t\t\t20170503074603_DDT615C36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1534-5807(02)00188-0","article-title":"The IGF-1\/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt","volume":"2","author":"Humbert","year":"2002","journal-title":"Dev. Cell"},{"key":"key\n\t\t\t\t20170503074603_DDT615C37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/bies.201100116","article-title":"A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology","volume":"34","author":"Bodai","year":"2012","journal-title":"Bioessays"},{"key":"key\n\t\t\t\t20170503074603_DDT615C38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JHD-120033","article-title":"Pizotifen activates ERK and provides neuroprotection in vitro and in vivo in models of Huntington's disease","volume":"1","author":"Sarantos","year":"2012","journal-title":"J. Huntingtons Dis."},{"key":"key\n\t\t\t\t20170503074603_DDT615C39","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1073\/pnas.120166397","article-title":"Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice","volume":"97","author":"Bibb","year":"2000","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170503074603_DDT615C40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.107.127183","article-title":"Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis","volume":"323","author":"Foster","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"key\n\t\t\t\t20170503074603_DDT615C41","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1096\/fj.10-173203","article-title":"Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model","volume":"25","author":"Kim","year":"2011","journal-title":"FASEB J."},{"key":"key\n\t\t\t\t20170503074603_DDT615C42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.nbd.2011.03.018","article-title":"Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease","volume":"43","author":"Carroll","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"key\n\t\t\t\t20170503074603_DDT615C43","doi-asserted-by":"crossref","first-page":"9544","DOI":"10.1523\/JNEUROSCI.1291-11.2011","article-title":"Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease","volume":"31","author":"Xiang","year":"2011","journal-title":"J. Neurosci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jnen\/62.1.25","article-title":"Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases","volume":"62","author":"Aboul-Enein","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"key\n\t\t\t\t20170503074603_DDT615C45","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1471-4159.2010.07069.x","article-title":"Myelin-associated glycoprotein protects neurons from excitotoxicity","volume":"116","author":"Lopez","year":"2011","journal-title":"J. Neurochem."},{"key":"key\n\t\t\t\t20170503074603_DDT615C46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1523\/JNEUROSCI.5204-08.2009","article-title":"Axonal protective effects of the myelin-associated glycoprotein","volume":"29","author":"Nguyen","year":"2009","journal-title":"J. Neurosci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C47","doi-asserted-by":"crossref","first-page":"7352","DOI":"10.1074\/jbc.M606508200","article-title":"AKT and CDK5\/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro","volume":"282","author":"Bogush","year":"2007","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503074603_DDT615C48","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1523\/JNEUROSCI.6595-10.2011","article-title":"Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion","volume":"31","author":"VonDran","year":"2011","journal-title":"J. Neurosci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08977190410001723308","article-title":"Brain-derived neurotrophic factor","volume":"22","author":"Binder","year":"2004","journal-title":"Growth Factors"},{"key":"key\n\t\t\t\t20170503074603_DDT615C50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","article-title":"Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules","volume":"118","author":"Gauthier","year":"2004","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170503074603_DDT615C51","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","article-title":"BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice","volume":"30","author":"Xie","year":"2010","journal-title":"J. Neurosci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1326-6-71","article-title":"Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction","volume":"6","author":"Giralt","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"key\n\t\t\t\t20170503074603_DDT615C53","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1523\/JNEUROSCI.1592-09.2009","article-title":"Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease","volume":"29","author":"Cummings","year":"2009","journal-title":"J. Neurosci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170503074603_DDT615C55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"Sanchez","year":"2003","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170503074603_DDT615C56","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2006-03-011437","article-title":"The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors","volume":"109","author":"Payne","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170503074603_DDT615C57","doi-asserted-by":"crossref","first-page":"14610","DOI":"10.1073\/pnas.1301342110","article-title":"Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin","volume":"110","author":"Caron","year":"2013","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170503074603_DDT615C58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmb.2012.09.011","article-title":"Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties","volume":"424","author":"Mishra","year":"2012","journal-title":"J. Mol. Biol."},{"key":"key\n\t\t\t\t20170503074603_DDT615C59","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200909067","article-title":"IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome","volume":"187","author":"Thompson","year":"2009","journal-title":"J. Cell. Biol."},{"key":"key\n\t\t\t\t20170503074603_DDT615C60","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1093\/hmg\/ddi340","article-title":"Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease","volume":"14","author":"Benn","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20170503074603_DDT615C61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2012.09.009","article-title":"Early tolerability and safety of fingolimod in clinical practice","volume":"323","author":"Ontaneda","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"key\n\t\t\t\t20170503074603_DDT615C62","volume-title":"Theory and Using Fresh Solutions. Regarding H&E Staining, Formalin Pigment Practice of Histological Techniques","author":"Bancroft","year":"2008"},{"key":"key\n\t\t\t\t20170503074603_DDT615C63","doi-asserted-by":"crossref","first-page":"8473","DOI":"10.1523\/JNEUROSCI.21-21-08473.2001","article-title":"Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice","volume":"21","author":"Li","year":"2001","journal-title":"J. Neurosci."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/23\/9\/2251\/14142642\/ddt615.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:06:28Z","timestamp":1716242788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article-lookup\/doi\/10.1093\/hmg\/ddt615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,2]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,12,2]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddt615","relation":{},"ISSN":["1460-2083","0964-6906"],"issn-type":[{"value":"1460-2083","type":"electronic"},{"value":"0964-6906","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,2]]}}}